April 27, 2021

Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration‐resistant prostate cancer patients during abiraterone/enzalutamide treatment

Key Points

Key points are not available for this paper at this time.

Abstract

MDT for oligoprogressive lesions is effective and may provide several benefits compared to switching from ARTA treatment to NEST. Patients with early progression while on ARTAs and inadequate PSA responses after MDT have a greater risk of rapid disease progression and poor survival, which necessitates intensified treatment.

Demander à l'IA

Bookmark

Cite This Study

Önal et al. (Tue,) studied this question.

synapsesocial.com/papers/69daab7ea6045d71bfa3db4c https://doi.org/https://doi.org/10.1002/pros.24132

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial2017 · 1,351 citations
2Characterising the castration-resistant prostate cancer population: a systematic review2011 · 867 citations
3Radiation-induced effects and the immune system in cancer2012 · 230 citations
4From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors2009 · 3,756 citations
5Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment: a mono-institutional experience2019 · 24 citations

Demander à l'IA

Bookmark